Where is Dynavax located?

Dynavax is located in Berkeley, United States .

Who is the current CEO of Dynavax?

Ryan Spencer and Eddie Gray are the current CEO of Dynavax.

How many employees does Dynavax have?

Dynavax has 408 employees as of Dec 31, 2023.

When was the latest funding round of Dynavax?

Dynavax's latest funding round was on Aug 27, 2021.

What is the annual revenue of Dynavax?

Annual revenue of Dynavax is $232M as on Dec 31, 2023.

Where does Dynavax rank among its competitors?

Dynavax ranks 2 amongst 316 active competitors.

Who are the top competitors of Dynavax?

Dynavax's top competitors are Adaptive Biotechnologies, Chimerix and Novavax.

Dynavax - 2025 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of products to prevent and treat infectious and inflammatory diseases and cancer. The lead candidate Heplisav-B Hepatitis B Vaccine combines TLR9 agonist and hepatitis B surface antigen. also developing DV2-HBV-25 for myocardial infarction, DV2-HBV-26 for immune-mediated herpes zoster, and others.

Website
Registered Address: Emeryville, California

Key Metrics

Founded Year

1996

Location

Berkeley, United States

Stage

Public

Total Funding

in 9 rounds

Latest Funding Round

Investors

Care Capital & 23 more

Ranked

2^nd among

Annual Revenue

as on Dec 31, 2023

Employee Count

as on Dec 31, 2023

Investment & Acquisitions

Rhein Biotech

Similar Companies

Adaptive Biotechnologies &

Exit Details

Public

Dynavax is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CIN: 0797.887.554 Belgium, Active	Jan 01, 2023	-	-	-
CIN: 1029142 United States, Deadpooled	Nov 05, 2000	$232M (as on Dec 31, 2023)	408 (as on Dec 31, 2023)	-
CIN: 330728374 United States, Active	Dec 26, 999	-	241 (as on Dec 31, 2022)	-

Get your free copy of Dynavax's company profile

Dynavax has raised a total funding of $73.9M over 9 rounds. Its latest funding round was a Post IPO round on Aug 27, 2021 for an undisclosed amount. 1 investor participated in its latest round, which include Great Point Partners, InterWest Partners, Red Abbey and CRG.

Dynavax has 24 institutional investors including Care Capital, and .

Here is the list of recent funding rounds of Dynavax:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Aug 27, 2021	Undisclosed	Post IPO	3438238	2611248	Bain Capital Life Sciences
May 11, 2021	$200M	Post IPO	1800207	2044973	-
Feb 20, 2018	$175M	Conventional Debt	8422070	8337581	CRG

Access funding benchmarks and valuations. Sign up today!

View details of Dynavax's funding rounds and investors

Dynavax's employee count trend

Dynavax has 408 employees as of Dec 23. The total employee count is 16.0% more than what it was in Dec 22. Here is Dynavax's employee count trend over the years:

Uncover Dynavax's growth story! Sign up today!

Access 秘密研究所 on any website

Our Google Chrome extension lets you view company details while browsing their websites

Top competitors of Dynavax include Adaptive Biotechnologies, Chimerix and Novavax. Here is the list of Top 10 competitors of Dynavax, ranked by 秘密研究所 score:

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Rock Springs Capital, HTIF听&补尘辫;听	78/100
2nd	Dynavax 1996, Berkeley (United States), Public	Developer of products to prevent and treat infectious and inflammatory diseases and cancer	$73.9M	Great Point Partners, InterWest Partners听&补尘辫;听	72/100
3rd	Chimerix 2002, Durham (United Kingdom), Acquired	Developer of antiviral oral therapeutics	$95.2M	Aisling Capital, InterWest Partners听&补尘辫;听	66/100
4th	Novavax 1987, Gaithersburg (United States), Public	Developer of novel vaccines using nanoparticles and matrix adjuvant technology	-	Foresite Capital, Prospect Venture Partners听&补尘辫;听	65/100
5th	Generate Biomedicines 2018, Somerville (United States), Series C	CRO focused on drug discovery & development services	$643M	T. Rowe Price, Flagship Pioneering听&补尘辫;听	64/100
6th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	GIC, Arch Venture Partners听&补尘辫;听	62/100
7th	VBI Vaccines 2001, Cambridge (United States), Public	Developer of vaccines for the treatment of infectious diseases	$65.1M	Perceptive Advisors, 5AM Ventures听&补尘辫;听	61/100
8th	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Care Capital, Bay Partners听&补尘辫;听	61/100
9th	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	HBM Partners, Redmile Group听&补尘辫;听	60/100
10th	Clear Labs 2014, Menlo Park (United States), Series D	Provider of food safety technologies for the identification of pathogens	$171M	T. Rowe Price, Redmile Group听&补尘辫;听	59/100